) has a strong presence in the diabetes care market. The company
has one of the broadest diabetes portfolios in the industry. The
company is working hard to develop its diabetes pipeline.
Novo Nordisk presented new data from a phase III study (DUAL
I) on its type II diabetes candidate, IDegLira, at the annual
meeting of the European Association for the Study of Diabetes
(EASD). IDegLira is a combination of insulin degludec, Tresiba
and Victoza, the once-daily human glucagon-like peptide-1 (GLP-1)
The DUAL I study showed a statistically significant reduction
in blood sugar levels (HbA1c) compared to Tresiba or Victoza
alone, with no weight gain and a low rate of hypoglycemia.
The effects of IDegLira on fasting and postprandial glucose
levels were also positive, resulting in a substantial overall
improvement in glycemic control versus Tresiba or Victoza alone.
Data from the study revealed that less than 7% sugar level
reduction was observed in 81% patients treated with IDegLira, 60%
patients treated with Victoza and 65% patients treated with
The DUAL program consists of two phase IIIa studies, namely,
DUAL I and DUAL II. DUAL II demonstrated that patients can
realize benefits from each of the components in the combination
product and reconfirmed the competitive profiles of Tresiba and
Novo Nordisk's Diabetes Care segment recorded sales growth of
14% in the second quarter of 2013. Modern insulins generated
strong revenues (up 15%) driven by NovoRapid (up 15%) and Levemir
(19%). Victoza witnessed sales growth of 32%.
Novo Nordisk carries a Zacks Rank #2 (Buy). Currently,
Roche Holding (
) look more attractive with a Zacks Rank #1 (Strong Buy).
AFFYMETRIX INC (AFFX): Free Stock Analysis
ACTELION LTD (ALIOF): Get Free Report
NOVO-NORDISK AS (NVO): Free Stock Analysis
ROCHE HLDG LTD (RHHBY): Get Free Report
To read this article on Zacks.com click here.